Search

TRANS-
FORMATION

Unlocked

At Elixir we believe that only by harnessing the power of transformation can there be real-world impact. We are re-imagining how radical medical technologies will breathe new life into vascular interventions, reshaping it for decades to come.

TRANSFORMATION.

TRANS-
FORMA-
TION
.

Unlocked.

At Elixir we believe that only by harnessing the power of transformation can there be real world impact. We are re-imagining how radical medical technologies will breathe new life into vascular interventions, reshaping it for decades to come.

We tackle big problems in vascular medicine.

We use transformation as a solution to improve health and quality of life for patients. By disrupting the status quo, we are going where others have given up.

CVDs are leading cause of death

17.9 million lives each year1

244.1 million

people were living with coronary artery disease2

About 6 million

patients undergo PCI (Percutaneous Coronary Intervention) every year

$407.3 billion

in direct and indirect cost in the United States3

805,000 annual heart attacks in US

200,000 are recurrent3

20% of patients experience an adverse event

within 5 years after PCI procedure4

These findings establish that the bioadaptor addresses the shortcomings of DES and bioresorbable scaffolds and collectively point to a technology-effectiveness standard not seen before. The finding of plaque changes is very exciting, pointing to a new effect and potential benefit of restoring vessel function.

Our technologies

DynamX bioadaptor is a coronary implant that is uniquely designed to not only restore blood flow, but to also unlock and uncage the vessel, allowing the artery to return to its natural physiology, motion and function while DynamX continues to provide dynamic support.

INTRAVASCULAR LITHOTRIPSY

Our novel intravascular lithotripsy catheter uses Hertz Contact Stress to harness the power of physics and mechanics to fracture calcium. Designed with deliverability, safety and simplicity of use in mind.

SITE-SPECIFIC ANTITHROMBOTIC THERAPY

We developed the world’s first site-specific antithrombotic therapy using two anticoagulants and an antiproliferative mTOR inhibitor. The technology is designed to address challenges associated with percutaneous coronary intervention (PCI), including management of thrombotic and bleeding risk.

News

EuroPCR 2024: Primary Outcomes from PINNACLE I Clinical Trial Establish Safety and Effectiveness of Elixir Medical’s Hertz Contact Intravascular Lithotripsy System for Calcium Fragmentation in Moderate to Severe Calcified Coronary Artery Lesions

Hertz Contact intravascular lithotripsy, as validated by PINNACLE I data, offers an effective and safe treatment option for patients with short procedure time, simple learning curve, and utility in treatment of a broad range of moderate to severe calcified lesions.

Read More »

EuroPCR 2024: Elixir Medical’s Late-Breaking 12-Month Data Demonstrate Significant Improvement in Safety and Effectiveness of World’s First Site-Specific Antithrombotic Therapeutic Compared to DES

Clinical research comparing DESyne BDS Plus, the world’s first triple drug-eluting coronary implant with site-specific antithrombotic therapeutic (TRx) coating versus a contemporary drug-eluting stent (DES), results demonstrated a statistically significant lower TLF rate with DESyne BDS Plus than DES.

Read More »

"Drug-eluting stents have been a blessing in the field of interventional cardiology. Nevertheless, the permanent cage, which prevents vessel remodeling, is a limitation. I believe that keeping the vessel as natural as possible is a positive feature (of the bioadaptor)."

Professor Antonio Colombo, MD

"The bioadaptor is a revolutionary innovation in percutaneous coronary intervention."

Dr. Shigeru Saito

“What sets the bioadaptor apart is that it allows the vessel to move more naturally. I think it does not restrict its natural motion. It is a much more physiologic implant than our traditional stents.”

Dr. Mladen Vidovich

"Although drug-eluting stents (DES) work well for treating coronary artery disease (CAD), they still have limitations even with the latest improvements. It's worth noting that even after five years, more than 20% of patients still experience chest pain or need to return to the hospital, which is a significant number. That's why I'm excited about the bioadaptor technology. It's a new kind of device that's different from traditional stents. This innovative approach can potentially overcome DES's limitations and improve how we treat CAD."

Manh-Hung Pham, MD

"Based on the fact that this device has so many wonderful characteristics and so much positive potential, this is something that every physician should be keen on using in his clinical practice."

Stefan Verheye, MD

"We are grateful to the clinical investigators who ran a world-class randomized controlled trial proving the safety and effectiveness of the DynamX bioadaptor against a leading third-gen DES. The findings of the BIOADAPTOR RCT show the leap-forward in patient care provided by uncaging arteries and continued dynamic vessel support, leading to restoration of motion and function that are critical to improving clinical outcomes for CAD patients."

Vinayak Bhat, PhD
"Drug-eluting stents have been a blessing in the field of interventional cardiology. Nevertheless, the permanent cage, which prevents vessel remodeling, is a limitation. I believe that keeping the vessel as natural as possible is a positive feature (of the bioadaptor)."
Professor Antonio Colombo, MD
“The bioadaptor is a revolutionary innovation in percutaneous coronary intervention.”
Dr. Shigeru Saito
“What sets the bioadaptor apart is that it allows the vessel to move more naturally. I think it does not restrict its natural motion. It is a much more physiologic implant than our traditional stents.”
Dr. Mladen Vidovich
“Although drug-eluting stents (DES) work well for treating coronary artery disease (CAD), they still have limitations even with the latest improvements. It's worth noting that even after five years, more than 20% of patients still experience chest pain or need to return to the hospital, which is a significant number. That's why I'm excited about the bioadaptor technology. It's a new kind of device that's different from traditional stents. This innovative approach can potentially overcome DES's limitations and improve how we treat CAD.”
Manh-Hung Pham, MD
“Based on the fact that this device has so many wonderful characteristics and so much positive potential, this is something that every physician should be keen on using in his clinical practice.”
Stefan Verheye, MD
“We are grateful to the clinical investigators who ran a world-class randomized controlled trial proving the safety and effectiveness of the DynamX bioadaptor against a leading third-gen DES. The findings of the BIOADAPTOR RCT show the leap-forward in patient care provided by uncaging arteries and continued dynamic vessel support, leading to restoration of motion and function that are critical to improving clinical outcomes for CAD patients.”
Vinayak Bhat, PhD
Previous slide
Next slide

PMN 1811 Rev A